Stopping circulatory vaccine-derived poliovirus in Kaduna state by scaling up special interventions in local government areas along rivers of interest- kamacha basin experience, 2013–2015

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Stopping circulatory vaccine-derived poliovirus in Kaduna state by scaling up special interventions in local government areas along rivers of interest- kamacha basin experience, 2013–2015
The Kamacha river is one of the five polio environmental surveillance sites in Kaduna State where 13 circulating vaccine-derived polioviruses (cVDPDs) were isolated between 2014 and 2015. Kamacha river account…
Authors: Audu I. Musa, Faisal Shuaib, Fiona Braka, Pascal Mkanda, Richard Banda, Charles Korir, Sisay G. Tegegne, Suleiman Abdullahi, Gregory C. Umeh, Terna I. Nomhwange, Hadiza Aliyu Iyal, Sambo Ishaku, Usman Adamu, Eunice Damisa, Murtala Bagana, Victor Gugong…
Citation: BMC Public Health 2018 18(Suppl 4):1303
Published on: 13 December 2018

Assessment of unmet needs to address noncompliant households during polio supplemental immunization activities in Kaduna state, 2014–2016

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Assessment of unmet needs to address noncompliant households during polio supplemental immunization activities in Kaduna state, 2014–2016
Despite concerted global efforts being made to eradicate poliomyelitis, the wild poliovirus still circulates in three countries, including Nigeria. In addition, Nigeria experiences occasional outbreaks of the …
Authors: Hadiza Aliyu Iyal, Faisal Shuaib, Madubu Dauda, Abdullahi Suleiman, Fiona Braka, Sisay G. Tegegne, Peter Nsubuga, Terna Nomhwange, Yared G. Yehualashet, Sambo Ishaku, Charity Warigon, Furera Zakari, Gregory Umeh, Lami Samaila, Basirat Abdullahi, Kulchumi Hammanyero…
Citation: BMC Public Health 2018 18(Suppl 4):1309
Published on: 13 December 2018

Conduct of vaccination in hard-to-reach areas to address potential polio reservoir areas, 2014–2015

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Conduct of vaccination in hard-to-reach areas to address potential polio reservoir areas, 2014–2015
The Global Vaccine Action Plan (GVAP) seeks to achieve the total realization of its vision through equitable access to immunization as well as utilizing the immunization systems for delivery of other primary h…
Authors: Samuel Bawa, Faisal Shuaib, Mahmoud Saidu, Adamu Ningi, Suleiman Abdullahi, Bashir Abba, Audu Idowu, Jibrin Alkasim, Kulchumi Hammanyero, Charity Warigon, Sisay G. Tegegne, Richard Banda, Charles Korir, Yared G. Yehualashet, Tesfaye Bedada, Chukwuji Martin…
Citation: BMC Public Health 2018 18(Suppl 4):1312
Published on: 13 December 2018

Impact of engaging security personnel on access and polio immunization outcomes in security-inaccessible areas in Borno state, Nigeria

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Impact of engaging security personnel on access and polio immunization outcomes in security-inaccessible areas in Borno state, Nigeria
Nigeria was polio free for almost 2 years but, with the recent liberation of areas under the captivity of insurgents, there has been a resurgence of polio cases. For several years, these inaccessible areas did…
Authors: Loveday Nkwogu, Faisal Shuaib, Fiona Braka, Pascal Mkanda, Richard Banda, Charles Korir, Samuel Bawa, Sule Mele, Mahmud Saidu, Hyelni Mshelia, Aliyu Shettima, Sisay G. Tegegne, Yared G. Yehualashet, Usman Adamu, Peter Nsubuga, Rui G. Vaz…
Citation: BMC Public Health 2018 18(Suppl 4):1311
Published on: 13 December 2018

Targeting the last polio sanctuaries with Directly Observed Oral Polio Vaccination (DOPV) in northern Nigeria, (2014–2016)

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Targeting the last polio sanctuaries with Directly Observed Oral Polio Vaccination (DOPV) in northern Nigeria, (2014–2016)
The declaration of poliomyelitis eradication as a programmatic emergency for global public health by the 65th World Health Assembly in 2012 necessitated innovations and strategies to achieve results. Review of…
Authors: Charles Korir, Faisal Shuaib, Usman Adamu, Samuel Bawa, Audu Musa, Abba Bashir, Ayodeji Isiaka, Adamu Ningi, Charity Warigon, Banda Richard, Braka Fiona, Mkanda Pascal, Nkwogu Loveday, Sisay G. Tegegne, Mohammed Abdul-Aziz, Abdullahi Suleiman…
Citation: BMC Public Health 2018 18(Suppl 4):1314
Published on: 13 December 2018

Lessons learnt from implementing community engagement interventions in mobile hard-to-reach (HTR) projects in Nigeria, 2014–2015

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Lessons learnt from implementing community engagement interventions in mobile hard-to-reach (HTR) projects in Nigeria, 2014–2015
The year 2014 was a turning point for polio eradication in Nigeria. Confronted with the challenges of increased numbers of polio cases detected in rural, hard-to-reach (HTR), and security-compromised areas of …
Authors: Kulchumi Isa Hammanyero, Samuel Bawa, Fiona Braka, Bassey Enya Bassey, Akinola Fatiregun, Charity Warigon, Yared G. Yehualashet, Sisay Gashu Tegene, Richard Banda, Charles Korir, Tesfaye Bedada Erbeto, Martin Chukwuji, Pascal Mkanda, Usman Saidu Adamu and Peter Nsubuga
Citation: BMC Public Health 2018 18(Suppl 4):1306
Published on: 13 December 2018

Acute flaccid paralysis (AFP) surveillance intensification for polio certification in Kaduna state, Nigeria: lessons learnt, 2015–2016

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Acute flaccid paralysis (AFP) surveillance intensification for polio certification in Kaduna state, Nigeria: lessons learnt, 2015–2016
Nigeria has made remarkable progress in its current efforts to interrupt wild poliovirus transmission despite the re-emergence of wild poliovirus in 2016. The gains made in Nigeria have been achieved through c…
Authors: Gregory C. Umeh, Faisal Shuaib, Audu Musa, Sisay G. Tegegne, Fiona Braka, Pascal Mkanda, Richard Banda, Usman Adamu, Terna I. Nomhwange, Eyiotoyo Arenyeka, Semeeh A. Omoleke, Ticha M. Johnson, Kehinde Craig, Ibrahim Idris, Hadiza Iyal, Ishaku G. Sambo…
Citation: BMC Public Health 2018 18(Suppl 4):1310
Published on: 13 December 2018

Towards an effective poliovirus laboratory containment strategy in Nigeria

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Towards an effective poliovirus laboratory containment strategy in Nigeria
The Global Commission for the Certification of the Eradication of Poliomyelitis will declare the world free of wild poliovirus transmission when no wild virus has been found in at least 3 consecutive years, an…
Authors: Johnson Muluh Ticha, Kolawole Olatunji Matthew, Abdullahi Walla Hamisu, Braka Fiona, Pascal Mkanda, Peter Nsubuga, Eberto Tesfaye, Kehinde Craig, Etsano Andrew, Obi Emelife, Faisal Shuaib, Akinkugbe Folasade, Johnson Adeniji, Usman Adamu, Mohammed Dallatu, Geoffrey Oyeyinka…
Citation: BMC Public Health 2018 18(Suppl 4):1304
Published on: 13 December 2018

Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016
Kano is one of the high-risk states for polio transmission in Northern Nigeria. The state reported more cases of wild polioviruses (WPVs) than any other state in the country. The Nigeria Demographic and Health…
Authors: Bashir Abba, Sule Abdullahi, Samuel Bawa, Kabir Ibrahim Getso, Imam Wada Bello, Charles Korir, Audu Musa, Fiona Braka, Adamu Ningi, Peter Nsubuga, Richard Banda, Sisay G. Tegegne, Faisal Shuaib, Usman Said Adamu and Sulaiman Haladu
Citation: BMC Public Health 2018 18(Suppl 4):1302
Published on: 13 December 2018

 

Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research
Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016
Kano is one of the high-risk states for polio transmission in Northern Nigeria. The state reported more cases of wild polioviruses (WPVs) than any other state in the country. The Nigeria Demographic and Health…
Authors: Bashir Abba, Sule Abdullahi, Samuel Bawa, Kabir Ibrahim Getso, Imam Wada Bello, Charles Korir, Audu Musa, Fiona Braka, Adamu Ningi, Peter Nsubuga, Richard Banda, Sisay G. Tegegne, Faisal Shuaib, Usman Said Adamu and Sulaiman Haladu
Citation: BMC Public Health 2018 18(Suppl 4):1302
Published on: 13 December 2018

 

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Dec 2018)

Research article
Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada
Timeliness in the administration of recommended vaccines is often evaluated using vaccine delays and provides more information regarding the susceptibility of children to vaccine-preventable diseases compared …
Authors: Marilou Kiely, Nicole Boulianne, Denis Talbot, Manale Ouakki, Maryse Guay, Monique Landry, Chantal Sauvageau and Gaston De Serres
Citation: BMC Public Health 2018 18:1364
Published on: 11 December 2018
 

Hepatitis B vaccination coverage among healthcare workers at a tertiary hospital in Rwanda

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content

Research note
Hepatitis B vaccination coverage among healthcare workers at a tertiary hospital in Rwanda
We evaluated post-vaccination immunity status and describe potential risk factors associated with the lack of response among healthcare workers (HCWs) at a tertiary care hospital in Kigali, Rwanda.
Authors: Claude Mambo Muvunyi, Jean De Dieu Harelimana, Osee Rurambya Sebatunzi, Aschariya Chinma Atmaprakash, Eric Seruyange, Florence Masaisa, Olivier Manzi, Martin Nyundo and Théobald Hategekimana
Citation: BMC Research Notes 2018 11:886
Published on: 13 December 2018

Pharmacovigilance: An Overview

Clinical Therapeutics
December 2018 Volume 40, Issue 12, p1957-2196
http://www.clinicaltherapeutics.com/current

Review
Pharmacovigilance: An Overview
Paul Beninger
p1991–2004
Published online: August 17, 2018
Abstract
Purpose
Pharmacovigilance (PV) is a relatively new discipline in the pharmaceutical industry. Having undergone rapid growth over the past 2 decades, PV now touches many other disciplines in the research and development enterprise. With its growth has come a heightened awareness and interest in the medical community about the roles that PV plays. This article provides insights into the background and inner workings of PV.
Methods
This narrative review covers the core PV activities and other major areas of the pharmaceutical enterprise in which PV makes significant contributions.
Findings
Drug safety monitoring activities were organized by the US Food and Drug Administration and academic medical centers in the early 1950s in response to growing concern over the occurrence of aplastic anemia and other blood dyscrasias associated with the use of chloramphenicol. This experience was codified in the 1962 Kefauver-Harris Amendments to the Federal Food, Drug and Cosmetic Act as adverse event evaluation and reporting requirements. The ensuing decades have seen the development of core PV functions for pharmaceutical companies: case management, signal management, and benefit-risk management. A broader scope of PV has developed to include the following major activities: support of patient safety during the conduct of clinical trials through assuring proper use of informed consent and institutional review boards (ethics committees); selection of the first safe dose for use in humans, based on pharmacologic data obtained in animal studies; development of the safety profile for proper use of a new molecular entity and appropriate communication of that information to the range of relevant stakeholders; attendance to surveillance activities through a set of signal management processes; monitoring the manufactured product itself through collaborative activities with manufacturing professionals; management of benefit–risk to assure appropriate use in medical care after marketing; and maintenance of inspection readiness as a corporate cultural process.
Implications
The extent and pace of change promise to accelerate with the integration of biomedical informatics, analytics, artificial intelligence, and machine learning. This progress has implications for the development of the next generation of PV professionals who will need to be trained in entirely new skill sets to lead continued improvements in the safe use of pharmaceuticals.

The views of ethics committee members and medical researchers on the return of individual research results and incidental findings, ownership issues and benefit sharing in biobanking research in a South Indian city

Developing World Bioethics
Volume 18, Issue 4  Pages: 307-432  December 2018
https://onlinelibrary.wiley.com/toc/14718847/current

Articles
The views of ethics committee members and medical researchers on the return of individual research results and incidental findings, ownership issues and benefit sharing in biobanking research in a South Indian city
Manjulika Vaz, Mario Vaz, Srinivasan K
Pages: 321-330
First Published: 17 May 2017

Mapping research ethics committees in Africa: Evidence of the growth of ethics review of health research in Africa

Developing World Bioethics
Volume 18, Issue 4  Pages: 307-432  December 2018
https://onlinelibrary.wiley.com/toc/14718847/current

Mapping research ethics committees in Africa: Evidence of the growth of ethics review of health research in Africa
Boitumelo Mokgatla, Carel IJsselmuiden, Doug Wassenaar, Mary Kasule
Pages: 341-348
First Published: 03 May 2017

Informed consent, community engagement, and study participation at a research site in Kigali, Rwanda

Developing World Bioethics
Volume 18, Issue 4  Pages: 307-432  December 2018
https://onlinelibrary.wiley.com/toc/14718847/current

Informed consent, community engagement, and study participation at a research site in Kigali, Rwanda
Jennifer Ilo van Nuil, Evelyne Kestelyn, Grace Umutoni, Lambert Mwambarangwe, Marie M. Umulisa, Janneke van de Wijgert, Raffaella Ravinetto
Pages: 349-356
First Published: 11 May 2017

Haitian people’s expectations regarding post‐disaster humanitarian aid teams’ actions

Developing World Bioethics
Volume 18, Issue 4  Pages: 307-432  December 2018
https://onlinelibrary.wiley.com/toc/14718847/current

Haitian people’s expectations regarding post‐disaster humanitarian aid teams’ actions
Lonzozou Kpanake, Ronald Jean‐Jacques, Paul Clay Sorum, Etienne Mullet
Pages: 385-393
First Published: 28 July 2017
Open Access

Community sensitization and decision‐making for trial participation: A mixed‐methods study from The Gambia

Developing World Bioethics
Volume 18, Issue 4  Pages: 307-432  December 2018
https://onlinelibrary.wiley.com/toc/14718847/current

Community sensitization and decision‐making for trial participation: A mixed‐methods study from The Gambia
Susan Dierickx, Sarah O’Neill, Charlotte Gryseels, Edna Immaculate Anyango, Melanie, annister‐Tyrrell, Joseph Okebe, Julia Mwesigwa, Fatou Jaiteh, René Gerrets, Raffaella Ravinetto, Umberto D’Alessandro, Koen Peeters Grietens
Pages: 406-419
First Published: 16 August 2017

Primary health care 40 years after Alma Ata 1978: addressing new challenges in a changing society

The European Journal of Public Health
Volume 28, Issue 6, December 2018
https://academic.oup.com/eurpub/issue/28/6

Editorials
Primary health care 40 years after Alma Ata 1978: addressing new challenges in a changing society
Jan De Maeseneer; Sally Kendall
Extract
In the 40 years since the Alma Ata Declaration the world has changed enormously. On the one hand, the world is much richer and healthier. On the other hand, those advances are unevenly spread, with growing numbers of people living precarious existences, many displaced from their homes. Health care has also changed. Advances in technology, including the advent of Big Data, coupled with adoption of evidence-based models of care have been transformational, especially for primary health care…

Global governance and the broader determinants of health: A comparative case study of UNDP’s and WTO’s engagement with global health

Global Public Health
Volume 14, 2019   Issue 2
http://www.tandfonline.com/toc/rgph20/current

Article
Global governance and the broader determinants of health: A comparative case study of UNDP’s and WTO’s engagement with global health
Unni Gopinathan, Nick Watts, Alexandre Lefebvre, Arthur Cheung, Steven J. Hoffman & John-Arne Røttingen
Pages: 175-189
Published online: 31 May 2018
 

Rohingya refugees in Bangladesh: the humanitarian response

Humanitarian Exchange Magazine
Number 73,  October 2018
https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/

Rohingya refugees in Bangladesh: the humanitarian response
More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, Mark Bowden outlines the historical, local and national political context in Bangladesh, and its operational implications. Amal de Chickera highlights the links between statelessness and displacement, and the international community’s failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. Puttanee Kangkun and John Quinley document the persistent persecution and denial of rights the Rohingya have faced for decades. Jeff Crisp reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the ‘localisation’ agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people’s needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees’ perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

Institutional Conflicts of Interest and Public Trust

JAMA
December 11, 2018, Vol 320, No. 22, Pages 2283-2387
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Institutional Conflicts of Interest and Public Trust
Francisco G. Cigarroa, MD; Bettie Sue Masters, PhD; Dan Sharphorn, JD
JAMA. 2018;320(22):2305-2306. doi:10.1001/jama.2018.18482
This Viewpoint discusses recent problems with undisclosed conflicts of interest and proposes broadening disclosure requirements beyond individuals to include the institutions funding the research.

Should Failure to Disclose Significant Financial Conflicts of Interest Be Considered Research Misconduct?

JAMA
December 11, 2018, Vol 320, No. 22, Pages 2283-2387
http://jama.jamanetwork.com/issue.aspx

Should Failure to Disclose Significant Financial Conflicts of Interest Be Considered Research Misconduct?
Jeffrey R. Botkin, MD, MPH
JAMA. 2018;320(22):2307-2308. doi:10.1001/jama.2018.17525
This Viewpoint proposes that failure of authors to completely disclose conflicts of interest (COIs) should be considered a form of research misconduct subject to institutional review and sanctions if appropriate to establish a basic standard of consistent COI reporting.

Lemons and Lyme

Journal of the Pediatric Infectious Diseases Society (JPIDS)
Volume 7, Issue 4, December 2018
https://academic.oup.com/jpids/issue

On Vaccination
Lemons and Lyme
Stanley A Plotkin
Extract
The world is a curious place, as you may have noticed, or, more accurately, people have curious opinions. One might think that a disease that is estimated to occur in more than 300000 people each year would be one that everybody would like to prevent [1], but that is not the case for Lyme disease, which, in this country, is caused by Borrelia burgdorferi sensu stricto.Figure 1 shows the geographical distribution of cases [1]. It is odd that there is a lobby against the development and deployment of a vaccine against the disease by people who…

The right to health

The Lancet
Dec 15, 2018   Volume 392Number 10164p2515-2654, e16
https://www.thelancet.com/journals/lancet/issue/current

Editorial
The right to health
The Lancet
Human Rights Day is recognised annually on Dec 10, and this year is especially important since it is the 70th anniversary of the day that the UN General Assembly adopted the Universal Declaration of Human Rights. The Declaration, through its 30 Articles, proclaims the rights that everyone is entitled to as a human being, regardless of race, colour, religion, sex, language, political or other opinion, national or social origin, property, birth, or other status. Today, Lawrence Gostin and colleagues, including the director-general of WHO, look back at the evolution of human rights in global health over the past 70 years and outline key messages for the future of health as a human right.

Gostin and colleagues describe how human rights became embedded in global health governance, beginning with WHO’s Constitution in 1946, which enshrined “the highest attainable standard of health” as one of the fundamental rights of every human being. But the Cold War superpowers took divergent positions on human rights and although the Declaration of Alma-Ata reaffirmed health as a right in 1978, many governments proved unable to implement appropriate policies. Gostin and colleagues describe how it was not until the AIDS pandemic in the 1980s that momentum grew behind universal access to treatment. Global health law, such as the WHO Framework Convention on Tobacco Control, and security, through the International Health Regulations, helped to embed health-related rights. Now, WHO considers universal health coverage through strengthened primary health care as core to the right to health and to achieving the sustainable development goals.

Recognition of the importance of human rights in protecting health is fundamental and is as crucial today as it was in 1948. As a common standard of achievement for all nations, promoting respect for these rights and freedoms is critical. But with constant rights violations taking place worldwide, and global threats such as climate change, armed conflict, and mass migration, the future of rights-based global health efforts is in the balance.

Global patterns of mortality in international migrants: a systematic review and meta-analysis

The Lancet
Dec 15, 2018   Volume 392Number 10164p2515-2654, e16
https://www.thelancet.com/journals/lancet/issue/current

Articles
Global patterns of mortality in international migrants: a systematic review and meta-analysis
Robert W Aldridge, Laura B Nellums, Sean Bartlett, Anna Louise Barr, Parth Patel, Rachel Burns,
Sally Hargreaves, J Jaime Miranda, Stephen Tollman, Jon S Friedland, Ibrahim Abubakar
Open Access
258 million people reside outside their country of birth; however, to date no global systematic reviews or meta-analyses of mortality data for these international migrants have been done. We aimed to review and synthesise available mortality data on international migrants.

Health impacts of parental migration on left-behind children and adolescents: a systematic review and meta-analysis

The Lancet
Dec 15, 2018   Volume 392Number 10164p2515-2654, e16
https://www.thelancet.com/journals/lancet/issue/current

Health impacts of parental migration on left-behind children and adolescents: a systematic review and meta-analysis
Gracia Fellmeth, Kelly Rose-Clarke, Chenyue Zhao, Laura K Busert, Yunting Zheng, Alessandro Massazza, Hacer Sonmez, Ben Eder, Alice Blewitt, Wachiraya Lertgrai, Miriam Orcutt, Katharina Ricci, Olaa Mohamed-Ahmed, Rachel Burns, Duleeka Knipe, Sally Hargreaves, Therese Hesketh,
Charles Opondo, Delan Devakumar
Open Access
Globally, a growing number of children and adolescents are left behind when parents migrate. We investigated the effect of parental migration on the health of left behind-children and adolescents in low-income and middle-income countries (LMICs).

The UCL–Lancet Commission on Migration and Health: the health of a world on the move

The Lancet
Dec 15, 2018   Volume 392Number 10164p2515-2654, e16
https://www.thelancet.com/journals/lancet/issue/current

The Lancet Commissions
The UCL–Lancet Commission on Migration and Health: the health of a world on the move
Ibrahim Abubakar, Robert W Aldridge, Delan Devakumar, Miriam Orcutt, Rachel Burns, Mauricio L Barreto, Poonam Dhavan, Fouad M Fouad, Nora Groce, Yan Guo, Sally Hargreaves, Michael Knipper, J Jaime Miranda, Nyovani Madise, Bernadette Kumar, Davide Mosca, Terry McGovern,
Leonard Rubenstein, Peter Sammonds, Susan M Sawyer, Kabir Sheikh, Stephen Tollman, Paul Spiegel, Cathy Zimmerman on behalf of the UCL–Lancet Commission on Migration and Health
Executive summary [excerpt]
With one billion people on the move or having moved in 2018, migration is a global reality, which has also become a political lightning rod. Although estimates indicate that the majority of global migration occurs within low-income and middle-income countries (LMICs), the most prominent dialogue focuses almost exclusively on migration from LMICs to high-income countries (HICs). Nowadays, populist discourse demonises the very same individuals who uphold economies, bolster social services, and contribute to health services in both origin and destination locations. Those in positions of political and economic power continue to restrict or publicly condemn migration to promote their own interests. Meanwhile nationalist movements assert so-called cultural sovereignty by delineating an us versus them rhetoric, creating a moral emergency.
In response to these issues, the UCL-Lancet Commission on Migration and Health was convened to articulate evidence-based approaches to inform public discourse and policy. The Commission undertook analyses and consulted widely, with diverse international evidence and expertise spanning sociology, politics, public health science, law, humanitarianism, and anthropology. The result of this work is a report that aims to be a call to action for civil society, health leaders, academics, and policy makers to maximise the benefits and reduce the costs of migration on health locally and globally. The outputs of our work relate to five overarching goals that we thread throughout the report…

History of Medicine: Influenza Cataclysm, 1918

New England Journal of Medicine
December 13, 2018   Vol. 379 No. 24
http://www.nejm.org/toc/nejm/medical-journal

Perspective
History of Medicine: Influenza Cataclysm, 1918
David M. Morens, M.D., and Jeffery K. Taubenberger, M.D., Ph.D.
This year marks the centennial of an influenza pandemic that killed 50 million to 100 million people globally — arguably the single deadliest event in recorded human history. Evidence suggests that another pandemic at least as severe may occur one day.

Economic impact of dengue in Mexico considering reported cases for 2012 to 2016

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 15 Dec 2018)

Research Article
Economic impact of dengue in Mexico considering reported cases for 2012 to 2016
Adriana Zubieta-Zavala, Malaquias López-Cervantes, Guillermo Salinas-Escudero, Adrian Ramírez-Chávez, José Ramos Castañeda, Sendy Isarel Hernández-Gaytán, Juan Guillermo López Yescas, Luis Durán-Arenas
| published 14 Dec 2018 PLOS Neglected Tropical Diseases
Abstract
Background
Given that dengue disease is growing and may progress to dengue hemorrhagic fever (DHF), data on economic cost and disease burden are important. However, data for Mexico are limited.
Methodology/Principal findings
Burden of dengue fever (DF) and DHF in Mexico was assessed using official databases for epidemiological information, disabilities weights from Shepard et al, the reported number of cases and deaths, and costs. Overall costs of dengue were summed from direct medical costs to the health system, cost of dengue to the patient (out-of-pocket expenses [medical and non-medical], indirect costs [loss of earnings, patient and/or caregiver]), and other government expenditures on prevention/surveillance. The first three components, calculated as costs per case by a micro-costing approach (PAATI; program, actions, activities, tasks, inputs), were scaled up to overall cost using epidemiology data from official databases. PAATI was used to calculate cost of vector control and prevention, education, and epidemiological surveillance, based on an expert consensus and normative construction of an ideal scenario.

Disability-adjusted life years (DALYs) for Mexico in 2016 were calculated to be 2283.46 (1.87 per 100,000 inhabitants). Overall economic impact of dengue in Mexico for 2012 was US$144 million, of which US$44 million corresponded to direct medical costs and US$5 million to the costs from the patient’s perspective. The estimated cost of prevention/surveillance was calculated with information provided by federal government to be US$95 million. The overall economic impact of DF and DHF showed an increase in 2013 to US$161 million and a decrease to US$133, US$131 and US$130 million in 2014, 2015 and 2016, respectively.
Conclusions/Significance
The medical and economic impact of dengue were in agreement with other international studies, and highlight the need to include governmental expenditure for prevention/surveillance in overall cost analyses given the high economic impact of these, increasing the necessity to evaluate its effectiveness.
Author summary
Dengue fever is caused by a flavivirus transmitted predominantly by the mosquito Aedes aegypti. Infection causes a broad spectrum of clinical signs and symptoms, from mild disease, such as dengue fever to a life threatening form known as dengue hemorrhagic fever. The disease is widespread in tropical regions. Measures such as vector control can slow the spread of infection, and most countries where the disease is endemic, Mexico included, have programs in place to this end. However, faced with other health issues that also require attention, it is important to quantify the suffering caused by dengue and also its economic costs. In this study, we aimed to produce detailed figures for Mexico to complement and refine those available from international studies. Such information will help guide how the money budgeted for health in dengue is spent.

The demographics of vaccine hesitancy in Shanghai, China

PLoS One
http://www.plosone.org/
[Accessed 15 Dec 2018]

Research Article
The demographics of vaccine hesitancy in Shanghai, China
Vaccine hesitancy has been little studied in low- and middle-income countries but is a potential concern because vaccine refusal may increase the burden of infectious diseases and impede control efforts. The aim of this study was to compare vaccine hesitancy between locals, long-time city residents, and non-locals, who have more recently moved to the city from either other urban or rural areas, in Shanghai, China
Jia Ren, Abram L. Wagner, Anna Zheng, Xiaodong Sun, Matthew L. Boulton, Zhuoying Huang, Brian J. Zikmund-Fisher
Research Article | published 13 Dec 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0209117

A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases

Science Translational Medicine
12 December 2018  Vol 10, Issue 471
http://stm.sciencemag.org/

Research Article   Diagnostics
A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases
By David Sebba, Alexander G. Lastovich, Melody Kuroda, Eric Fallows, Joshua Johnson, Ambroise Ahouidi, Anna N. Honko, Henry Fu, Rex Nielson, Erin Carruthers, Cyrille Diédhiou, Doré Ahmadou, Barré Soropogui, John Ruedas, Kristen Peters, Miroslaw Bartkowiak, N’Faly Magassouba, Souleymane Mboup, Yanis Ben Amor, John H. Connor, Kristin Weidemaier
Science Translational Medicine12 Dec 2018 Restricted Access
A multiplexed point-of-care diagnostic using surface-enhanced Raman scattering detects Ebola, Lassa, and malaria in blood and serum samples.
Discerning febrile diseases
Many infectious diseases present with common clinical symptoms, such as fever, which complicates diagnosis at the point of need. Sebba and colleagues developed an assay using surface-enhanced Raman scattering (SERS) nanotags to distinguish Ebola virus infections from Lassa and malaria. The no-wash triplex assay workflow adds a small volume of blood and buffer to dried SERS reagents and delivers a readout within 30 min. The assay detected parasite- and virus-specific antigens spiked into the blood, Ebola infections in nonhuman primates, and Ebola and malaria infections in human blood samples collected from endemic regions during field testing. Although further testing is required, this assay could be useful during febrile disease outbreaks.
Abstract
Hemorrhagic fever outbreaks such as Ebola are difficult to detect and control because of the lack of low-cost, easily deployable diagnostics and because initial clinical symptoms mimic other endemic diseases such as malaria. Current molecular diagnostic methods such as polymerase chain reaction require trained personnel and laboratory infrastructure, hindering diagnostics at the point of need. Although rapid tests such as lateral flow can be broadly deployed, they are typically not well-suited for differentiating among multiple diseases presenting with similar symptoms. Early detection and control of Ebola outbreaks require simple, easy-to-use assays that can detect and differentiate infection with Ebola virus from other more common febrile diseases. Here, we developed and tested an immunoassay technology that uses surface-enhanced Raman scattering (SERS) tags to simultaneously detect antigens from Ebola, Lassa, and malaria within a single blood sample. Results are provided in <30 min for individual or batched samples. Using 190 clinical samples collected from the 2014 West African Ebola outbreak, along with 163 malaria positives and 233 negative controls, we demonstrated Ebola detection with 90.0% sensitivity and 97.9% specificity and malaria detection with 100.0% sensitivity and 99.6% specificity. These results, along with corresponding live virus and nonhuman primate testing of an Ebola, Lassa, and malaria 3-plex assay, indicate the potential of the SERS technology as an important tool for outbreak detection and clinical triage in low-resource settings.

T Cell Memory to Vaccination

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 15 Dec 2018)

Open Access  Editorial
T Cell Memory to Vaccination
by Stephen M Todryk
Vaccines 2018, 6(4), 84; https://doi.org/10.3390/vaccines6040084 (registering DOI) – 14 December 2018
Abstract
Most immune responses associated with vaccination are controlled by specific T cells of a CD4+ helper phenotype which mediate the generation of effector antibodies, cytotoxic T lymphocytes (CTLs), or the activation of innate immune effector cells. A rapidly growing understanding of the generation, maintenance, activity, and measurement of such T cells is leading to vaccination strategies with greater efficacy and potentially greater microbial coverage

 

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
The Economist
http://www.economist.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
New Yorker
http://www.newyorker.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 15 Dec 2018
Dec. 13, 2018
Politics
Renewed Battle Over Using Fetal Tissue in Medical Research
Lawmakers clashed over science, ethics and politics at a House hearing Thursday on using fetal tissue in critically important medical research, as the Trump administration reviews the government’s ongoing support for such studies.
 
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 15 Dec 2018
[No new, unique, relevant content]
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 15 Dec 2018
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al
 
Brookings
http://www.brookings.edu/
Accessed 15 Dec 2018
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center
Accessed 15 Dec 2018
December 12, 2018
Global Consortium Supporting Low- and Middle-Income Countries to Make Evidence-Based Healthcare Investment Decisions Receives $14.5 Million Boost
A global consortium working with low- and middle-income countries as they aim to make healthcare investment decisions that reflect the best value for money has received a $14.5 million grant from the Bill & Melinda Gates Foundation, announced the Center for Global Development today.
[See Milestones above for detail]

CSIS
https://www.csis.org/
Accessed 15 Dec 2018
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 15 Dec 2018
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 08 December 2018

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_8 Dec 2018

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly disease [U.K.] :: Johnson & Johnson Announces Participation in New Collaboration Funded by the UK to Support Vaccines for Pandemic Preparedness

Milestones :: Perspectives

Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly disease [U.K.]
Ebola and Lassa fever are among the deadly diseases to be tackled in a pioneering new UK vaccine centre.
Press release   1 December 2018
:: The UK’s first-ever dedicated Vaccines Manufacturing Innovation Centre will ensure the UK life sciences industry remains at the forefront of worldwide efforts to tackle life-threatening diseases, including Ebola
:: The centre will be built in Oxford, creating more than 50 jobs in the local area
:: Through the modern Industrial Strategy, the government is investing £66 million through UK Research and Innovation in the centre to help make Britain the best place in the world for innovators, including new treatments to help people live longer, healthier and happier lives through the Life Sciences Sector Deal
:: Led by the Jenner Institute, a partnership between the University of Oxford and the Pirbright Institute, the new centre has been awarded funding by UK Research and Innovation of £66 million through the UK government’s Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing challenge.

… Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme. The centre will be further supported by expertise and training from GE Healthcare.

The core research teams will be drawn from academia and industry and will include significant new contributions from the London School of Hygiene & Tropical Medicine and Imperial College London as well as the University of Oxford. The programme will also benefit from access to technologies and intellectual property created by the partners.

::::::
 
Johnson & Johnson Announces Participation in New Collaboration Funded by the UK to Support Vaccines for Pandemic Preparedness
Janssen joins forces with UK government and multiple academic and industrial partners to support creation of Vaccine Manufacturing and Innovation Centre
New Brunswick, N.J., Dec. 3, 2018 – Johnson & Johnson today announced that Janssen Vaccines & Prevention B.V., part of its Janssen Pharmaceutical Companies, will participate in a new collaboration with the UK government and multiple partners from academia and industry that will result in the UK’s first-ever dedicated Vaccine Manufacturing and Innovation Centre (VMIC).

UK Research and Innovation will invest £66 million in the centre as part of the Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing programme. VMIC will enable the development and manufacture of vaccines for clinical trials and for emergency outbreak response and preparedness.

“Infectious diseases with pandemic potential need to be proactively addressed, in advance of outbreaks occurring, and developing new vaccines is a central part of any preparedness strategy,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “We applaud the UK’s leadership in mobilizing partners from the across the public, private and academic sectors to tackle this challenge.”

The VMIC is planned to be operational in Oxford by 2022, and will be a purpose-built facility capable of supporting multiple technologies, allowing for academic and industry collaboration on the development and manufacture of vaccines.

Three academic institutions will be engaged in VMIC: the Jenner Institute (a partnership between the University of Oxford and the Pirbright Institute), Imperial College, and the London School of Hygiene & Tropical Medicine. Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme (MSD), who will also share their extensive experience in the design and construction of such a facility, and in vaccine manufacturing and development. GE Healthcare will provide in-kind support on engineering and training.

“We are delighted to collaborate on this important initiative with the UK government and this impressive consortium of partners,” said Johan Van Hoof, M.D., Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D and Managing Director, Janssen Vaccines & Prevention B.V., who will be joining the governing board of VMIC. “Only by working in common cause can we achieve the goal of pandemic preparedness. If we take action now, working together, we can prevent the pandemics of the future. We are delighted to support this vital mission.”

The VMIC is being launched to enable the rapid manufacture of vaccines in the event of an epidemic affecting the UK. It will also enable a rapid global response to emerging highly infectious pathogens. Additionally, VMIC aims to develop new technologies such as personalized cancer vaccines and vectors for gene therapy.

“Improving the development, production and application of new vaccines against infectious diseases requires expertise and collaboration across academia and industry,” said UK Research and Innovation Chief Executive Professor Sir Mark Walport. “The Vaccine Manufacturing and Innovation Centre will play an important role in bringing expertise from industry and academia together to ensure we are prepared to respond to the threats of serious infections, including viruses with the potential to cause major national or global epidemics.”

PREVENT Guidance

Milestones :: Perspectives

PREVENT Guidance

Developed by the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies (PREVENT) Working Group, Johns Hopkins Berman Institute of Bioethics
September 2018. :: 96 pages
PDF: http://vax.pregnancyethics.org/s/PREVENT-Web.pdf
Overview
This Guidance provides a roadmap for the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens. The Guidance is a product of the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies (PREVENT) Working Group—a multidisciplinary, international team of 17 experts specializing in bioethics, maternal immunization, maternal-fetal medicine, obstetrics, pediatrics, philosophy, public health, and vaccine research and policy— in consultation with a variety of external experts and stakeholders.

The Guidance begins by setting forth an aspirational vision and makes the case for its moral importance. We then specify 22 concrete recommendations, organized around three key areas: public health preparedness, R&D, and vaccine delivery.

The recommendations are directed at a range of actors, including global and national policymakers, regional and national regulatory authorities, funders and sponsors, vaccine manufacturers, research institutions, trial networks and research groups, individual researchers, oversight bodies, ethics review committees, community advisory boards, and civil society organizations.

 

Cholera in Yemen: A Case Study of Epidemic Preparedness and Response

Milestones :: Perspectives

Cholera in Yemen: A Case Study of Epidemic Preparedness and Response
Johns Hopkins Center for Humanitarian Health
2018 :: 108 pages
PDF: http://www.hopkinshumanitarianhealth.org/assets/documents/CHOLERA_YEMEN_REPORT_LONG_Low_Res_Dec_4_2018.pdf
Overview
In 2015, the United Nations declared Yemen a Level 3 emergency. On September 28, 2016, a large-scale cholera outbreak began. Between April 27, 2017 and July 1, 2018, more than one million suspected cases in two waves were reported. In the last decade, several large-scale and high-mortality cholera outbreaks have occurred during complex humanitarian emergencies including in Iraq, Somalia, and South Sudan. While the issues of “what to do” to control cholera are largely known, context-specific practices on “how to do it” in order to surmount challenges to coordination, logistics, insecurity, access, and politics, remain needed. During the Yemen cholera outbreak response, questions arose on how to effectively respond to a cholera outbreak at a national scale during an existing emergency. The main objective of this report was to identify lessons learned from the preparedness and detection phase to the end of second wave of the cholera epidemic in Yemen to better prepare for future outbreaks in Yemen and similar contexts.

Excerpts from Executive Summary
…The use of the oral cholera vaccine (OCV) was slowed by the lack of cholera response planning and technical knowledge among the Ministry of Public Health and Population (MoPHP) and partners. The lack of an updated cholera preparedness and response plan meant that OCV was not integrated into the response mindset and thus, there was a lack of technical knowledge and familiarly with OCV. OCV was not sufficiently discussed during the first wave, and was requested then rejected by the MoPHP during the second wave based on differing conceptions of the overall scale of distribution. The March 2018 plan is the first document that mentions

an OCV strategy, based on a January 2018 risk assessment. The MoPHP then made a successful

request to the Global Task Force for Cholera Control in April 2018 for 4.6 million doses for preventative use against future surges of cholera….

CONCLUSIONS:
The cholera response in Yemen was and remains extremely complicated and challenging for a variety of political, security, cultural, and environmental reasons. The study team recognizes these challenges and commends the government, international and national organizations, and the donors for working to find solutions in such a difficult context. There are no easy fixes to these challenges, and the conclusions and recommendations are meant to be constructive and

practical, taking into account the extreme limitations of working in Yemen during an active conflict.

The findings were consistent across respondents and methods. The study team found that several areas gained strength throughout the second wave, including: an extensive operational footprint which reached into insecure areas; the strengthening of the collaborations between WHO and UNICEF and the health and WASH clusters; the initiation of a funding mechanism through the World Bank which enabled a timely response at scale; the revitalization of the WASH strategy; and, eventual consensus and use of OCV.

Conversely, the major gaps of this response are rooted in weaknesses in preparedness and the early strategies developed in the first wave. An after-action review after the first wave could have institutionalized these areas in order to prevent a much larger second wave.

The World Bank’s commitment to the cholera response provides the rationale for major investment in bolstering the preparedness activities in Yemen and other conflict-affected

contexts which would go far for addressing the foundational gaps discussed in this case study.

 

TOP 20 RECOMMENDATIONS FOR FUTURE PREPAREDNESS AND RESPONSE

[Excerpt]

ORAL CHOLERA VACCINATION

  1. Global recommendation: Different scenarios for OCV according to varying contexts should be integrated ahead of time into national cholera preparedness plans in general. This is especially important for “fragile” countries where there is a possibility of humanitarian emergencies developing or continuing.
  2. Global and Yemen-specific recommendation: In complex and insecure environments like Yemen, smaller, geographically-targeted OCV campaigns should be anticipated and planned…

 

Ebola – Democratic Republic of the Congo

Milestones :: Perspectives

Ebola – Democratic Republic of the Congo

18: Situation report on the Ebola outbreak in North Kivu  5 December 2018
[Excerpts]
…Case Management
:: Since the beginning of the response, 5 649 samples have been tested (including repeat samples).
:: The ETCs continue to provide therapeutics under the MEURI protocol, in collaboration with the MoH and the Institut National de Recherche Biomédicale (INRB), together with supportive care measures. WHO is providing technical clinical expertise on-site and is assisting with the creation of a data safety management board.
:: New patients continue to be treated in ETCs. As of 3 December 2018, 144 confirmed cases have recovered and been discharged. Bed occupancy was 63% in Beni ETC, 75% in Beni transit centre and 56% in Butembo ETC. All confirmed cases are being treated with a therapeutic under the MEURI framework after evaluation by clinical expert committee. All hospitalized patients receive food and psychological support.
…Implementation of ring vaccination protocol
:: Vaccination continued on 3 December 2018 in Beni, Katwa, Butembo, Komanda, Vuhovi and Lubero, with 568 persons vaccinated, including 114 contacts, 175 contacts of contacts and 279 first line workers.
:: As of 3 December 2018, the cumulative number of people vaccinated,is 39 845.

DONs  Ebola virus disease – Democratic Republic of the Congo   6 December 2018
[Excerpt]
…Ebola virus disease in women and children
Concerns have been raised regarding the disproportionate number of women and children infected during this outbreak (Figure 3). To date, females accounted for 62% (280/450) of overall cases where sex was reported. Of all female cases, 83% (230/277) were aged ≥15 years. Of these women, at least 18 were pregnant, and an additional seven were breastfeeding or recently delivered at the time of infection. There have been 27 cases among infants less than one year of age, with 70% (19) of these being boys, and 21 fatalities (age-specific case fatality of 78%). There were also nine cases in infants aged less than one month. Children less than 15 years of age accounted for 24% (106/447) of cases.

There are likely a multitude of factors contributing towards this disproportionate disease burden observed in women and children. These include: exposure within formal and informal health facilities, involvement in traditional burial practices, transmission within family groups (including transmission between mothers caring for children), differences in health seeking behaviour, as well as the impact of ongoing conflict on the underlying population structure in affected areas. Among those with available information, commonly identified risk factors reported by cases include: having contact to a known case (224/320, 70%), having attended funerals (121/299, 40%) and having visited/admitted to a health facility before onset of EVD (46/139, 33%). Of note, 46% of female cases (84/181) reported having attended funerals, in contrast to 31% of male cases (37/118).

A concurrent increase in cases of malaria and the inadequate accompanying IPC in health settings are also likely to be contributory to the high rates of EVD among children. The recent conclusion of a four-day malaria control campaign in Beni on 2 December aimed at preventing further malaria deaths, as well as lessen the burden on health centres in order to address this potential source of transmission.

The MoH, WHO, are actively working with UNICEF and other partners to address the increased risks observed in women (including pregnant or breastfeeding women) and young children, and further strengthen measures to prevent and manage infections in these groups…

 

Emergencies

Emergencies
 
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 04 December 2018 [GPEI]
:: The circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak in Syria, which was first detected in 2017, has been successfully stopped. The announcement came at the heels of an official outbreak response assessment, comprising of experts in public health, epidemiology and virology, who reviewed evidence and concluded the outbreak was closed. Read the full statement here.
 
 
:: On 27 November 2018, the 19th IHR Emergency Committee including members, advisers, and invited Member States convened to discuss the status of international spread of poliovirus. The Committee unanimously agreed that the risk of polio spread continues to be a Public Health Emergency of International Concern (PHEIC) and proposed an extension of Temporary Recommendations for an additional three months. The Committee expressed concern that complacency to achieving a polio-free world could now become the biggest risk to the effort and urged that all countries and partners regard polio eradication as an emergency.  “We have the tools, we need to focus on what works, we need to get to every child,” commented Prof. Helen Rees, Chairperson of the Committee.  “The reality is that there is no reason why we should not be able to finish this job, but we have to keep at it.”  Prof. Rees and the Committee urged countries, donors and partners to continue their support, until a polio-free world is achieved, cautioning that failure to eradicate polio would lead to global resurgence of the disease, with potentially as many as 200,000 new cases occurring annually within ten years.  “We have achieved eradication of a disease once before, with smallpox,” Rees concluded.  “The world is a much better place without smallpox.  It’s now more urgent than ever that we redouble our efforts and finish this job once and for all as well.”  The recommendations come amid the notification of the fourth cVDPV circulation in DRC, which underscores the need for sustained partnership, funding, and socio-political resolve. Read the full WHO statement including the Temporary Recommendations.

:: The Africa Regional Commission for the Certification of poliomyelitis eradication (ARCC) was held in Nairobi, Kenya, from 12-16 November 2018. Made up of 16 health experts, recommendations were made to ten countries to address issues of disease surveillance gaps, inaccessibility and insecurity. Read the recommendations here.

The Technical Advisory Groups (TAG) on Polio Eradication in Horn of Africa and Lake Chad Basin convened recently, to review the current status of polio outbreaks in both the regions and provide guidance on the next phase of the outbreak response.

::Featured on http://www.polioeradication.org: Coffee with Polio Experts – Dr Mohammad Al Safadi, Technical Officer for Polio Outbreak Preparedness and Response, talks about the tactics and strategies used to stop the Syria outbreaks of 2013, 2014, and the most recent outbreak of 2017, which was compounded by accessibility, security, and conflict issues.

:: Call for nomination of experts to serve on the Polio Research Committee to provide guidance to the Director of the Polio Department at WHO HQ on the research and development aspects in poliovirus eradication. Read the details here.

The GPEI report to the upcoming WHO Executive Board (in January) has been published.  The report provides a status update on polio eradication, summarizing programmatic, epidemiological and financial challenges to securing a lasting polio-free world, and introduces the concept of a new extended strategic plan to achieve global certification by 2023, taking into account the fact that circulation of wild poliovirus has not yet been interrupted.  Read the report here.

 
 
Summary of new viruses this week:
Afghanistan – one wild poliovirus type 1 (WPV1) case and two positive WPV 1 environmental samples.
Pakistan – nine WPV1 positive environmental samples.
DRC – two cases of circulating vaccine-derived poliovirus type 2 (cVDPV2).
Nigeria – four cases of cVDPV2.
Somalia – one positive cVDPV2 environmental sample. See country sections below for more details.

::::::

Djibouti carries out mass immunization to protect children against polio, amid outbreaks in the Horn of Africa

5 December 2018 – Early analysis of campaign data points to a successful vaccination round in a polio-free country at risk of possible importation.
In the last week of October, Djibouti’s Ministry of Health, working with WHO, UNICEF and other partners, successfully carried out the country’s first polio National Immunization Days (NIDs) since 2015.
While Djibouti has not had a case of polio since 1999, the recent outbreak of polio in neighbouring countries in the Horn of Africa, and the low levels of routine immunization coverage in some areas in the country, are indications that Djibouti is still at risk if poliovirus spreads through population movements. Other countries in the Horn of Africa are already cooperating to control the existing outbreak and to reduce the risk of spread, and given that Djibouti is on a major migration route in the Horn of Africa, it makes a lot of sense for Djibouti to join this coordinated response…

::::::

Countries of the Americas seek to strengthen measures to keep the Region free of polio and move towards global eradication (12/05/2018)
PAHO convenes strategic partners and 140 public health professionals from 22 countries in the Region, in Guatemala this week. If polio is not eradicated there could be up 200,000 new cases worldwide each year within ten years.

::::::

Global Polio Eradication Initiative – Certification of poliovirus eradication
November 2018 :: Statement
Global Commission for the Certification of Poliomyelitis Eradication (GCC) reviews criteria for certification
Attaining and sustaining a world free from all polioviruses
On 29-31 October 2018, the Global Commission for Certification of Poliomyelitis Eradication (GCC) met to review the criteria that will need to be met to achieve global certification of wild poliovirus (WPV) eradication.

As the world approaches successful eradication of WPV transmission, the GCC’s work takes on urgency, including consideration of circulating vaccine-derived polioviruses (cVDPVs). While these are not a new phenomenon, they become more significant, as does the need for effective containment of all polioviruses in laboratories and vaccine manufacturing facilities. The GCC has recommended a process of sequential certification of WPV eradication and confirmation of the absence of VDPVs, when the data become available. The Director General has accepted the GCC recommendation for sequential certification.

While the operational and programmatic aspects of achieving and sustaining a world free of all polioviruses – be they wild or vaccine-derived – have been well-established, the GCC is focusing its discussions on the necessary verification processes associated with this eventual achievement. Following the certification that WPV transmission has been stopped – and after OPV has been withdrawn – the absence of VDPVs will also need to be validated.

The assessment that all WPV transmission has been interrupted globally is the critical step which will mark the launch of preparations for cessation of all oral polio vaccine (OPV) use. Inadequate routine immunization levels coupled with subnational gaps in surveillance in high-risk countries continue to be the main risk factors for the emergence or continuation of cVDPVs. Both risk factors must be addressed. However, the only and surest way to prevent cVDPVs in the future is to rapidly stop OPV use, which can only occur after the successful eradication of WPVs. As such, the polio eradication program now has two urgent tasks – to eradicate WPVs as quickly as possible and to stop the use of OPV globally.

With no wild poliovirus type 3 (WPV3) reported globally since November 2012 (from Nigeria), the GCC concluded that the world could be ready to certify the eradication of WPV3, and urged the GPEI and Member States to ensure that full documentation is available to achieve this goal. This type-specific global certification would ideally follow a similar process as that used for the certification of WPV2 eradication in 2015. The GCC recommended that the GPEI conduct a comprehensive review of the implications of such sequential certification, and report back to it in 2019.

The GCC also continues to evaluate evidence that polioviruses will be rigorously contained where they are being held (in a limited number of research or diagnostics laboratories, and in vaccine manufacturing facilities). The Containment Advisory Group and the Containment Working Group guide the operationalization of this work, through implementation of the WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use (GAPIII).

The WHO Director-General has accepted the outcomes and recommendations of the GCC and these will be incorporated into a global strategy for eradication covering the period 2019-2023 (currently being developed in a broad consultative process, and to be presented to the World Health Assembly in May 2019). The full report from the GCC’s meeting will subsequently be made available upon publication at www.polioeradication.org.

The GCC’s work and efforts will assure the independent verification that transmission of all polioviruses has been interrupted globally, and that all necessary safeguards to sustain a polio-free world have been put in place.

Additional background:
The GCC is independent of WHO and of involvement in national polio vaccination implementation or polio surveillance programmes. WHO Regions are eligible for certification following the absence of WPV from any country in that region from any population source in the presence of certification-standard surveillance. Regional certification is conducted by Regional Certification Commissions (RCCs). Global certification will follow the successful certification of all six WHO regions, and will be conducted by the GCC.
As at 2018, four regions have been certified as free of WPVs: Region of the Americas (1994), the Western Pacific Region (2000), the European Region (2002),  and the South-East Asia Region (2014).
  For more information, please see:
http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/certification/
http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/

::::::
::::::

Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.
 
 
WHO Grade 3 Emergencies  [to 8 Dec 2018]
Democratic Republic of the Congo
:: 18: Situation report on the Ebola outbreak in North Kivu  5 December 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo   6 December 2018
[See Milestones above for more detail]
 
 
Bangladesh – Rohingya crisis
:: Weekly Situation Report 53 -30 November 2018
[Excerpt]
HEALTH OPERATIONS
OCV Campaign:
After completion of 2nd week of OCV campaign, 163,441 ( 101.5%.) received the vaccination. Among them 119,649 (107.3%) were FDMN beneficiaries and 43,792 (88.5%) from host community. Out of total target of 328, 556, 49.7% vaccination completed. Among them 53.2% were FDMN beneficiaries and 42.3% from host community. Besides the major portion of the FDMN and HC: Registered camps, No-man’s land and people engaged in different activities adjacent to camps are being covered.
Rapid Convenience monitoring through house to house:
In total 2116 beneficiaries were interviewed till 28 November 2018. Evaluated coverage was 92.5%. The main reasons not being vaccinated were beneficiaries not at home (32%), not aware of campaign (23%) and beneficiaries too busy (14%). The main means of mobilization were majhee and FDMN mobilizers (46.2), megaphone (30.1) and moni flag (17.5)…
 
 
Syrian Arab Republic
:: WHO update on reported chemical event in Aleppo, Syria   29 November 2018
 
 
Myanmar – No new announcements identified
Nigeria – No new announcements identified
Somalia – No new announcements identified
South Sudan – No new announcements identified
Yemen – No new announcements identified
 
::::::
 
WHO Grade 2 Emergencies  [to 8 Dec 2018]
Sudan
:: WHO Member States sign Khartoum Declaration on Sudan and Bordering Countries: Cross-Border Health Security
4 December 2018 – Six countries in WHO’s Eastern Mediterranean and African Regions have signed a declaration committing themselves to strengthening preparedness and response to public health threats and events across borders in an effort to further the implementation of the International Health Regulations (IHR 2005) and enhance global health security. The Khartoum Declaration on Sudan and Bordering Countries: Cross-Border Health Security was signed by Chad, Egypt, Ethiopia, Libya, South Sudan and Sudan on 22 November 2018 in Khartoum, Sudan…
 
 
Brazil (in Portugese) – No new announcements identified
Cameroon  – No new announcements identified
Central African Republic  – No new announcements identified
Ethiopia – No new announcements identified
Hurricane Irma and Maria in the Caribbean – No new announcements identified
Iraq – No new announcements identified
occupied Palestinian territory – No new announcements identified
Libya – No new announcements identified
MERS-CoV – No new announcements identified
Niger – No new announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new announcements identified
Ukraine – No new announcements identified
Zimbabwe – No new announcements identified
 
 
WHO-AFRO: Outbreaks and Emergencies Bulletin, Week 48: 24-30 November 2018
The WHO Health Emergencies Programme is currently monitoring 57 events in the region. This week’s edition covers key ongoing events, including:
:: Yellow fever in South Sudan
:: Ebola virus disease in the Democratic Republic of the Congo
:: Cholera in Zimbabwe
:: Hepatitis E in Central African Republic
:: Humanitarian crisis in Ethiopia.
 
::::::
 
WHO Grade 1 Emergencies  [to 8 Dec 2018]
Afghanistan
Chad
Indonesia – Sulawesi earthquake 2018
Kenya
Lao People’s Democratic Republic
Mali
Namibia – viral hepatitis
Peru
Philippines – Tyhpoon Mangkhut
Tanzania
 
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Yemen
:: Yemen: Al Hudaydah Update Situation Report No. 15, Reporting period: 14 November – 2 December 2018

Syrian Arab Republic   No new announcements identified.

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia  No new announcements identified.
Somalia  – No new announcements identified.

 ::::::

 “Other Emergencies”
Indonesia: Central Sulawesi EarthquakeNo new announcements identified.
 
::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
 
EBOLA/EVD  [to 8 Dec 2018]
http://www.who.int/ebola/en/
:: 18: Situation report on the Ebola outbreak in North Kivu  5 December 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo   6 December 2018
[See Milestones above for more detail]
 
 
MERS-CoV [to 8 Dec 2018]
http://who.int/emergencies/mers-cov/en/
No new announcements identified.
 
 
Yellow Fever  [to 8 Dec 2018]
http://www.who.int/csr/disease/yellowfev/en/
No new announcements identified.
Zika virus  [to 8 Dec 2018]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.
 
 

WHO & Regional Offices [to 8 Dec 2018]

WHO & Regional Offices [to 8 Dec 2018]
7 December 2018
News Release
New WHO report highlights insufficient progress to tackle lack of safety on the world’s roads

5 December 2018
News Release
Health benefits far outweigh the costs of meeting climate change goals

3 December 2018
Statement
WHO statement for COP24

::::::
 
Weekly Epidemiological Record, 7 December 2018, vol. 93, 49 (pp. 661–680)
:: Meeting of the Strategic Advisory Group of Experts on Immunization, October 2018 – Conclusions and recommendations

::::::
 
GIN November 2018  pdf, 1.22Mb 3 December 2018

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
Selected Featured News
:: Ethiopia launches Human Papillomavirus Vaccine for 14 year old girls  06 December 2018
:: Niger vaccinates 152,000 people against cholera in high-risk areas  06 December 2018
:: African countries test their capacity to respond to a deadly global flu pandemic  04 December 2018
:: Uganda and DRC bordering districts agree to intensify cross-border surveillance to tackle Ebola  03 December 2018
:: Tackling cholera outbreaks in North-east humanitarian emergencies   03 December 2018

WHO Region of the Americas PAHO
:: Countries of the Americas seek to strengthen measures to keep the Region free of polio and move towards global eradication (12/05/2018)
PAHO convenes strategic partners and 140 public health professionals from 22 countries in the Region, in Guatemala this week. If polio is not eradicated there could be up 200,000 new cases worldwide each year within ten years. 

WHO South-East Asia Region SEARO
– No new announcement identified

WHO European Region EURO
:: Health is a human right 07-12-2018
:: Preventing hospital-acquired infections in eastern Ukraine saves lives 06-12-2018
:: Interparliamentary Assembly of Member Nations of the Commonwealth of Independent States supports international measures to stop illicit tobacco trade 04-12-2018

WHO Eastern Mediterranean Region EMRO
:: Initiating hepatitis C treatment in Afghanistan  5 December 2018
:: Djibouti carries out mass immunization to protect children against polio 5 December 2018

WHO Western Pacific Region
– No new announcement identified

 

CDC/ACIP [to 8 Dec 2018]

CDC/ACIP [to 8 Dec 2018]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for Friday, December 7, 2018
Public Health Response to an Avian Influenza H7N8 Outbreak in Commercial Turkey Flocks— Indiana, 2016
Surveillance for influenza among responders to an outbreak of avian influenza in turkeys in Indiana in 2016 did not detect any human illnesses. Highly pathogenic avian influenza outbreaks are animal health emergencies that require aggressive control measures. If the virus causing an outbreak is capable of causing human illness, then there could be health risks for the responders. The Indiana State Department of Health and the Dubois County Health Department worked together to monitor the health of people who responded to an outbreak of avian influenza in commercial turkey flocks in 2016. No human cases of avian influenza were detected.